MyeloMATCH MM1YA-CTG01 (Acute Myeloid Leukemia) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if 2 different experimental drug combinations can improve outcomes for people who are newly diagnosed with AML. We want to compare the outcomes from the standard treatment (cytarabine + daunorubicin) to the following experimental regimens:

  • Venetoclax + cytarabine + daunorubicin
  • Venetoclax + azacitidine
What is the Condition Being Studied?

Acute Myeloid Leukemia (AML)

Who Can Participate in the Study?

Adults ages 18-59 who:

  • Are newly diagnosed with AML
  • Have not received any previous treatment for AML
  • Are registered to the Master Screening and Re-Assessment Protocol (myeloMATCH MSRP)

For more information, contact the study team at nick.jeffries@duke.edu.

Age Group
Adults

What is Involved?

If you choose to join this study, you will get a random assignment (random chance) to 1 of 3 groups:

  • Group 1: venetoclax + cytarabine + daunorubicin (experimental regimen); OR
  • Group 2: venetoclax + azacitidine (experimental regimen); OR
  • Group 3: cytarabine + daunorubicin (standard treatment)

Study Details

Full Title
Myelomatch MM1YA-CTG01: A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL
Principal Investigator
Hematologic Oncologist
Protocol Number
IRB: PRO00116800
NCT: NCT05554393
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment